Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial

Bonderup, Ole K.; Hansen, Jane Møller; Teglbjærg, Peter Stubbe; Christensen, Lisbet Ambrosius; Fallingborg, Jan

doi:10.1136/gut.2008.156513

Cited by 151 publications

(98 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical response was maintained in 33/40 (83%) patients who received budesonide compared to 11/40 (28%) patients who [92] [94] . However, 6 mo maintenance therapy did not alter the subsequent course, as the relapse risk after withdrawal of 24 wk maintenance treatment was similar to that observed after 6 wk induction therapy, and the median time to relapse was equal in the two groups (39 d versus 38 d) [97] .…”

Section: Therapy and Prognosismentioning

confidence: 94%

“…In clinical practice, tapering doses of budesonide to 3-6 mg/d have been used as maintenance therapy and may well control clinical symptoms. There is now evidence for such a strategy in CC, and two studies have proven maintenance therapy with budesonide 6 mg/d for 6 mo is well-tolerated and superior to placebo [97,98] . A total of 80 patients, who had responded to openlabel budesonide, were randomized to budesonide 6 mg/d or placebo for 6 mo.…”

Section: Therapy and Prognosismentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and management of microscopic colitis

Tysk¹,

Bohr²,

Nyhlin³

et al. 2008

WJG

View full text Add to dashboard Cite

Microscopic colitis, comprising collagenous and lymphocytic colitis, is characterized clinically by chronic watery diarrhea, and a macroscopically normal colonic mucosa where diagnostic histopathological features are seen on microscopic examination. The annual incidence of each disorder is 4-6/100 000 inhabitants, with a peak incidence in 60-70-year-old individuals and a noticeable female predominance for collagenous colitis. The etiology is unknown. Chronic diarrhea, abdominal pain, weight loss, fatigue and fecal incontinence are common symptoms, which impair the health-related quality of life of the patient. There is an association with other autoimmune disorders such as celiac disease, diabetes mellitus, thyroid disorders and arthritis. Budesonide is the best-documented shortterm treatment, but the optimal long-term strategy needs further study. The long-term prognosis is good and the risk of complications including colonic cancer is low.

show abstract

Section: Therapy and Prognosismentioning

confidence: 94%

Section: Therapy and Prognosismentioning

confidence: 99%

Diagnosis and management of microscopic colitis

Tysk¹,

Bohr²,

Nyhlin³

et al. 2008

WJG

View full text Add to dashboard Cite

show abstract

“…21,22 Two other randomized placebo-controlled trials conducted by Bonderup et al 23 and Miehlke et al 24 showed that clinical remission and histological response could be maintained in most patients with budesonide at a dose of 6 mg/day for 6 months, with an 83% response rate.…”

Section: Histological Diagnosismentioning

confidence: 99%

Microscopic colitis: A literature review

Clara

Magnago

Ferreira

et al. 2016

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Microscopic colitis (MC) refers to chronic inflammation of the colon which is characterized by histologic changes at the level of a radiologically and endoscopically normal mucosa. It is a common cause of chronic non-bloody diarrhea that occurs primarily in older individuals; however, there are few studies in the literature with strong scientific evidence compared to other inflammatory bowel diseases (IBD), which limits the knowledge of physicians and pathologists. This article aims to review the information on MC, describing diagnostic methods and drugs available for treatment. We conducted a search of the Pubmed database and CAPES Portal using the keywords "microscopic colitis", "collagenous colitis", "lymphocytic colitis", and "review" for selection of articles published between 1996 and 2015 related to the topic. Based on the studies discussed in this review, we conclude that MC is a relatively new gastrointestinal disorder, most studies are incipient particularly with respect to pathophysiology and immunology, and budesonide is the best documented short-term treatment. However, further studies are needed to elucidate the best strategy for treatment in the long term.

show abstract

“…These findings are consistent with the previously reported intraepithelial lymphocytosis in terminal ileum in adult patients with CC. 26,27 While clinical trials have shown the efficacy of budesonide treatment in adult patients with CC, [28][29][30][31][32] treatment for children appears to be largely empiric with various agents (Table 1). Overall, sulfasalazine, mesalazine, and cholestyramine were either ineffective or only partially effective.…”

Section: Discussionmentioning

confidence: 99%